ANI Pharmaceuticals, Inc.

NasdaqGM:ANIP Stock Report

Market Cap: US$1.2b

ANI Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 5/6

ANI Pharmaceuticals has a total shareholder equity of $480.6M and total debt of $285.2M, which brings its debt-to-equity ratio to 59.4%. Its total assets and total liabilities are $920.8M and $440.1M respectively. ANI Pharmaceuticals's EBIT is $48.2M making its interest coverage ratio 2.3. It has cash and short-term investments of $247.1M.

Key information

59.4%

Debt to equity ratio

US$285.24m

Debt

Interest coverage ratio2.3x
CashUS$247.05m
EquityUS$480.61m
Total liabilitiesUS$440.14m
Total assetsUS$920.75m

Recent financial health updates

Recent updates

ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028

Aug 02

Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

Jun 10
Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

Jun 10

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

Feb 17
These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Nov 15
Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Sep 22
Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Feb 22
Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt

Oct 28
We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt

ANI Pharma launches generic Prochlorperazine maleate tablets

Aug 29

ANI Pharmaceuticals' generic dexamethasone tablets get FDA approval

Aug 16

ANI Pharmaceuticals Q2 2022 Earnings Preview

Aug 05

ANI Pharmaceuticals (NASDAQ:ANIP) Is Making Moderate Use Of Debt

Apr 29
ANI Pharmaceuticals (NASDAQ:ANIP) Is Making Moderate Use Of Debt

Financial Position Analysis

Short Term Liabilities: ANIP's short term assets ($555.5M) exceed its short term liabilities ($140.0M).

Long Term Liabilities: ANIP's short term assets ($555.5M) exceed its long term liabilities ($300.2M).


Debt to Equity History and Analysis

Debt Level: ANIP's net debt to equity ratio (7.9%) is considered satisfactory.

Reducing Debt: ANIP's debt to equity ratio has reduced from 92.5% to 59.4% over the past 5 years.

Debt Coverage: ANIP's debt is well covered by operating cash flow (39.5%).

Interest Coverage: ANIP's interest payments on its debt are not well covered by EBIT (2.3x coverage).


Balance Sheet


Discover healthy companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.